Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders. Established with a commitment to scientific excellence and leadership in CNS research, Acadia's proprietary drug discovery platform has enabled the creation of a robust portfolio targeting conditions such as Parkinson's disease psychosis, Alzheimer's disease psychosis, Rett syndrome, and schizophrenia.
Acadia's pivotal achievements include the development and commercialization of NUPLAZID, the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE, the first and only FDA-approved drug for the treatment of Rett syndrome. The company's clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric symptoms in CNS disorders.
Situated in San Diego, one of the largest biotechnology hubs in the United States, Acadia benefits from proximity to over 400 companies and renowned research institutions like the Salk Institute for Biological Studies. This strategic location supports Acadia's mission to bring groundbreaking therapies to patients in need.
Financially, Acadia has shown significant growth, with total revenues reaching $205.8 million for the first quarter of 2024, reflecting a 74% year-over-year increase, largely due to the strong market performance of NUPLAZID and the addition of DAYBUE. The company continues to invest in its pipeline and commercial operations, maintaining a solid cash position with $470.5 million in cash, cash equivalents, and investment securities as of March 31, 2024.
Recent highlights include participation in major healthcare conferences, strategic appointments to enhance leadership in research and development, and ongoing efforts to expand the reach of DAYBUE beyond the U.S. market. Acadia’s unwavering dedication to advancing neuroscience and improving patient outcomes underscores its long-term growth potential and commitment to innovation in the biopharmaceutical landscape.
Acadia Pharmaceuticals (NASDAQ: ACAD) has granted inducement awards to twelve new employees under its 2024 Inducement Plan. The awards, approved by the Compensation Committee on January 13, 2025, include non-qualified stock options to purchase 23,782 shares at $17.90 per share and 13,928 restricted stock units (RSUs).
The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over four years, with 50% vesting at the second anniversary and the remaining 50% in two equal annual installments thereafter. Both awards are contingent on continued employment with Acadia.
The company specializes in neuroscience breakthroughs and has developed FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. Their clinical-stage pipeline includes programs for Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric symptoms in CNS disorders.
Acadia Pharmaceuticals (NASDAQ: ACAD) provided key business updates at the 43rd Annual J.P. Morgan Healthcare Conference. The company projects over $1 billion in net sales for 2025 from its two main products, NUPLAZID and DAYBUE.
Key developments include the submission of a marketing authorization application for DAYBUE to the European Medicines Agency (EMA), with expected approval in Q1 2026. The company plans to initiate Managed Access Programs in Europe by Q2 2025, marking its first international revenue stream.
Pipeline milestones for 2025-2026 include: completion of COMPASS PWS Phase 3 study enrollment for ACP-101 in Prader-Willi Syndrome (Q4 2025), RADIANT Phase 2 study completion for ACP-204 in Alzheimer's disease psychosis (Q1 2026), and initiation of a Phase 2 study for ACP-204 in Lewy Body Dementia (Q3 2025). The company will host its first R&D Day in mid-2025.
Acadia Pharmaceuticals (NASDAQ: ACAD) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency for trofinetide to treat Rett syndrome in patients two years and older. If approved, it would be the first therapy for Rett syndrome in the EU. The drug is already approved in the US and Canada.
The application is supported by positive results from the Phase 3 LAVENDER study of 187 participants. The study met its co-primary endpoints, showing statistically significant improvements in both the Rett Syndrome Behaviour Questionnaire (RSBQ) total score and Clinical Global Impression-Improvement (CGI-I) scale score at week 12. The key secondary endpoint measuring communication and social behavior was also met.
Rett syndrome affects approximately 1 in 10,000-15,000 female births worldwide. It's a rare neurodevelopmental disorder typically caused by a MECP2 gene mutation, characterized by normal early development followed by regression in communication skills and purposeful hand use.
Acadia Pharmaceuticals (ACAD) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Catherine Owen Adams will present on January 14, 2025, at 9:00 a.m. PT / 12:00 p.m. ET. The presentation will be available via live webcast on Acadia.com's investor section, with a recording accessible for approximately one month afterward.
Acadia is a neuroscience company that has developed pioneering treatments, including the first FDA-approved drug for Parkinson's disease psychosis-related hallucinations and delusions, and the first approved treatment for Rett syndrome in the US and Canada. The company's clinical-stage pipeline focuses on Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric symptoms in CNS disorders.
Acadia Pharmaceuticals (NASDAQ: ACAD) has granted inducement awards to thirteen new employees on December 4, 2024. The awards include non-qualified stock options to purchase 38,568 shares at $17.17 per share and 22,264 restricted stock units (RSUs). The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over four years, with 50% vesting at the second anniversary and the remaining in two annual installments.
The awards were approved by the Compensation Committee under Acadia's 2024 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4). The company focuses on neuroscience breakthroughs and has developed FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome.
Acadia Pharmaceuticals (ACAD) has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million before fees and expenses. Per a previous agreement announced on November 5, 2024, Neuren Pharmaceuticals will receive one-third of the net proceeds. The company plans to utilize the funds to support its commercial operations, R&D programs in central nervous system and rare disease, and future business development.
Acadia specializes in neuroscience breakthroughs and has developed FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. Their clinical-stage pipeline includes programs for Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric symptoms in CNS disorders.
Acadia Pharmaceuticals (NASDAQ: ACAD) has appointed Thomas Andrew Garner as Chief Commercial Officer, effective immediately. Garner brings over 25 years of pharmaceutical industry experience and will lead Acadia's commercial strategy and operations, focusing on growth and portfolio expansion across U.S. and international markets.
Garner joins from Lexicon Pharmaceuticals, where he served as SVP and CCO. Previously, he spent 21 years at Bristol Myers Squibb in various senior roles, including leading their U.S. Cardiovascular unit with revenues exceeding $10 billion. The company also announced Holly Valdiviez's promotion to SVP, Neuropsychiatric Franchise, overseeing NUPLAZID sales and marketing.
Acadia Pharmaceuticals (NASDAQ: ACAD) has secured an exclusive worldwide license agreement with Saniona for SAN711, a first-in-class GABAA-α3 positive allosteric modulator. The company plans to develop SAN711 for essential tremor treatment, with Phase 2 studies expected to begin in 2026. Under the agreement, Saniona will receive a $28 million upfront payment plus potential milestone payments up to $582 million and tiered royalties ranging from mid-single digits to low double digits on net sales. The milestone payments include up to $147 million for development achievements and up to $435 million tied to annual sales thresholds.
Acadia Pharmaceuticals (Nasdaq: ACAD) has announced its participation in two major investor conferences in December 2024. The company will present at Citi's 2024 Global Healthcare Conference in Miami on December 3 at 10:15 a.m. ET, and the 7th Annual Evercore HealthCONx Conference in Coral Gables on December 4 at 2:35 p.m. ET. Both fireside chats will be available via webcast on Acadia.com.
Acadia specializes in neuroscience breakthroughs and has developed FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. Their current clinical-stage research focuses on Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric symptoms in CNS disorders.
Acadia Pharmaceuticals (Nasdaq: ACAD) announced that its Compensation Committee granted inducement awards to 23 new employees on November 8, 2024. The awards include 70,571 non-qualified stock options at $17.66 per share and 40,731 restricted stock units (RSUs). The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over four years, with 50% vesting after two years and the remaining in two annual installments, all subject to continued employment.
FAQ
What is the current stock price of Acadia Pharmaceuticals (ACAD)?
What is the market cap of Acadia Pharmaceuticals (ACAD)?
What does Acadia Pharmaceuticals Inc. specialize in?
Where is Acadia Pharmaceuticals headquartered?
What are some of Acadia's key products?
What recent financial performance did Acadia report?
What are Acadia's current research focuses?
What recent achievements has Acadia Pharmaceuticals announced?
How does Acadia support the Rett syndrome community?
What is the significance of Acadia's location in San Diego?
How has Acadia's product portfolio grown recently?
What is Acadia’s approach to drug discovery?
